Child deaths in Vietnam fall dramatically
Child deaths in Vietnam fall dramatically
20 November 2009
Through its commitment to immunisation and other child health interventions, Vietnam has drastically reduced its child deaths, putting the country well on track to reach the Millennium Development Goal 4 (MDG) before the 2015 deadline.
GAVI Alliance support helps put Vietnam on track for Millennium Development Goal 4
Hanoi, 20 November 2009 - Through its commitment to immunisation and other child health interventions, Vietnam has drastically reduced its child deaths, putting the country well on track to reach the Millennium Development Goal 4 (MDG) before the 2015 deadline.
Statistics provided by UNICEF show that over the last two decades, deaths among Vietnamese children have dropped from 56 per 1000 in 1990 to 15 in 2007 .
The MDG4 is aimed at reducing by two thirds the number of deaths of children under five by 2015; one of the eight goals set by the United Nations.
National vaccination programme
"Immunisation is at the heart of the Vietnamese Government's strategy for improving child health," said Dr Trinh Quan Huan, Vice Minister of Health of Vietnam
A national vaccination programme against measles, pertussis (whooping cough), tetanus and other vaccine-preventable diseases has played a central role in achieving the reduction.
Routine immunisation coverage is 93% for diphtheria, tetanus and pertussis (DTP3), matching the rates of most industrialised countries.
"Immunisation is at the heart of the Vietnamese Government's strategy for improving child health," said Dr Trinh Quan Huan, Vice Minister of Health of Vietnam and member of the GAVI Alliance Board.
"We have been able to use GAVI support to simultaneously expand our immunisation programmes in urban and rural areas, while improving the delivery of health services in general."
20th anniversary of Child Rights
Dr Huan made the announcement at the GAVI Partners' Forum in Hanoi, a meeting of some 400 immunisation experts. Participants include ministers of health from over 30 countries and representatives from donor countries, civil society, industry, and development and research agencies.
"With our celebration of the 20th anniversary of the Convention on the Rights of the Child today, it is very rewarding to see that Vietnam is making such progress. The country is working effectively with GAVI partners to provide its children with what every child is entitled to -- the right to equal access to good health," said human rights advocate and GAVI Board Chair Mary Robinson.
Worldwide trend
Julian Lob-Levyt, CEO of the GAVI Alliance, said that Vietnam was a good example of a worldwide trend among low-income nations who are steadily improving their immunisation rates.
"What we see in Vietnam is similar to many other places-countries are taking the tools provided with GAVI support and using them to ensure that more children have an opportunity to live and thrive," he said.
"Immunisation is one of the most cost-effective ways to save lives, improve health, and ensure long-term prosperity. Vietnam illustrates the success possible through an effective immunisation programme."
Dr Lob-Levyt noted other countries that are performing extraordinarily well in immunisation include Nepal, Congo, Djibouti, Gambia, Bhutan, Eritrea, and Bangladesh.
"This would have been unheard of even five years ago. It's remarkable," he said.
"Vietnam's outstanding achievement in consistently reaching its children with an ever-increasing number of vaccines and other life-saving interventions is an inspiring example of what can be done to realise children's right to health," said Pascal Villeneuve, Associate Director of Programmes, UNICEF
Cost-effective interventions
"We know how tough it is for developing countries to sustain the delivery of child health interventions such as immunisation, given limited resources. Vietnam has risen to this challenge and is proving that immunisation, together with other cost-effective interventions, makes all the difference in improving the health of children," said Daisy Mafubelu, Assistant Director-General for Family and Community Health at the World Health Organization.
"Immunisation and other child survival interventions are good indications of health system performance. Vietnam's outstanding achievement in consistently reaching its children with an ever-increasing number of vaccines and other life-saving interventions is an inspiring example of what can be done to realise children's right to health," said Pascal Villeneuve, Associate Director of Programmes at UNICEF.
Special award
Vietnam's child health achievements were recognised at the Hanoi meeting with a special award citing the outstanding performance by the country. Fourteen other low-income countries received similar awards.
The GAVI Alliance, which includes among its members WHO and UNICEF, has provided Vietnam with US$ 14.4 million for vaccines, US$ 3.2 million for injection safety, and US$ 1 million for immunisation services.
GAVI has also approved Vietnam's request for an additional US$ 21.3 million to introduce the pentavalent vaccine, a single dose of which contains antigens that protect against diphtheria, pertussis, tetanus, hepatitis B and Haemophilus influenzae type b (Hib).Through mid-2009, GAVI has invested US$ 12.2 million for strengthening the health system, notably through health worker training.
New data on GAVI support
New data also released this week shows that by the end of 2009, more than four million premature deaths caused by pertussis, Hib and hepatitis B will have been prevented globally through GAVI support. With funds from donor nations, philanthropy and the contributions of low-income governments, GAVI partners immunised an additional 256 million children.
At the Hanoi GAVI Partners' Forum, officials from UNICEF, which procures the majority of vaccines financed through GAVI, noted that GAVI efforts to pool and increase demand for vaccines have led to a significant drop in the average weighted price of the pentavalent vaccine.
It has fallen from a 2004 price of US$ 3.65 per dose to a 2010 price of US$ 2.94 and is expected to be US$ 2.83 by 2012.
The GAVI CEO welcomed the price decline but expressed GAVI's intention to achieve more.
"The price drop has come later than we had hoped and it needs to fall further," he said. "But this is a clear indication that our market-shaping efforts work. This will help us achieve our mission that is to save children's lives and protect people's health by increasing access to immunisation in poor countries."
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024